[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial Review
September 1998

Bullous PemphigoidThe Latest in Diagnosis, Prognosis, and Therapy

Author Affiliations

From the Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio.

Arch Dermatol. 1998;134(9):1137-1141. doi:10.1001/archderm.134.9.1137

When I was a dermatology resident in the mid-1980s, I became fascinated, some might say obsessed, with autoimmune blistering diseases. At that time, interest in and advances in the understanding of these diseases were on the rise. Since then, enormous leaps in our understanding of the pathophysiological features of these autoimmune blistering diseases have been made in large part because of the widespread application of sophisticated molecular biological techniques to ascertain the target antigens against which autoimmune responses are directed. Our appreciation of the full spectrum of bullous pemphigoid (BP), the most common of all the autoimmune blistering diseases, has grown as a function of advances in not only the basic science arena but also the clinical arena. In this editorial I focus my comments on key points relevant to caring for patients with BP, with the understanding that many of these clinical advances have been made possible by advances in basic science.

First Page Preview View Large
First page PDF preview
First page PDF preview
×